316
Table 19.2
Clinical studies on interventional treatments of resistant hypertension in chronic kidney disease patients
Hering et al.
Ott et al.
Kiuchi et al.
Wallbach et al.
Patients (
n)
15
27
30
23
Age (years)
61 ± 9
63 ± 9
55 ± 10
61 ± 10
Number of antihypertensive drugs
5.6 ± 1.3
6.2 ± 1.1
4.6 ± 1.3
6.6 ± 1.6
Method of intervention
RDN
RDN
RDN
B AT
Baseline
6 months after intervention
Baseline
12 months after intervention
Baseline
24 months after intervention
Baseline
6 months after intervention
Office SBP (mmHg)
174 ± 22
142***
156 ± 12
136 ± 19***
185 ± 18
131 ± 15***
161 ± 32
144 ± 32**
Office DBP (mmHg)
91 ± 16
76***
82 ± 13
74 ± 14**
107 ± 13
87 ± 9***
87 ± 15
77 ± 17**
eGFR (ml/min)
31 ± 9
29 ± 7
48 ± 12
49 ± 15
62 ± 23
88 ± 40***
54 ± 28
60 ± 26*
UACR(mg/g creatinine)
592 ± 955
355 ± 276
99
11***
48
45*
Proteinuria(mg/g creatinine)
284
136*
SBP
systolic blood pressure,
DBP
diastolic blood pressure,
eGFR
estimated glomerular filtration rate,
RDN
renal denervation,
BAT
baroreflex activation ther
apy,
UACR
urinary albumin-to-creatinine ratio; *p<0.05; **p<0.01; ***p<0.001
M. Adamczak et al.